Table 3.
Clinical event rates at 3‐year follow‐up categorized by abnormal glucose metabolism diagnosed by either diagnostic approach
| Based on OGTT or HbA1c and FPG | P log‐rank | HR (95%CI) | ||
|---|---|---|---|---|
| Abnormal glucose metabolism | Normal glucose metabolism | |||
| Total n = 988 | n = 330 | n = 658 | ||
| Target vessel failurea | 29 (8.8) | 36 (5.5) | 0.044 | 1.64 (1.01–2.68) |
| Death | 6 (1.8) | 13 (2.0) | 0.87 | 0.92 (0.35–2.42) |
| Cardiac death | 3 (0.9) | 2 (0.3) | 0.21 | 2.99 (0.50–17.88) |
| Any MI | 18 (5.5) | 24 (3.7) | 0.18 | 1.51 (0.82–2.79) |
| Target vessel MI | 17 (5.2) | 18 (2.7) | 0.051 | 1.90 (0.98–3.70) |
| Periprocedural MI | 15 (4.5) | 9 (1.4) | 0.002 | 3.34 (1.46–7.63) |
| Revascularization, any | 26 (7.9) | 50 (7.6) | 0.88 | 1.04 (0.65–1.66) |
| Target vessel revascularization | 13 (4.0) | 25 (3.8) | 0.92 | 1.04 (0.53–2.03) |
| MACE | 29 (8.8) | 47 (7.2) | 0.33 | 1.26 (0.79–2.00) |
Note: Data are n(%).
Abbreviations: CI, confidence interval; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HR, hazard ratio; MACE, major adverse cardiac events; MI, myocardial infarction; OGTT, oral glucose tolerance testing.
a
Target vessel failure was the main study endpoint.